Pyridoxal Phosphate (Pyridoxal 5 Phosphate)

This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE).

Also Known As:

Networked: 229 relevant articles (7 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Clayton, Peter T: 3 articles (10/2015 - 04/2005)
2.	Danpure, Christopher J: 3 articles (10/2015 - 04/2003)
3.	Selhub, Jacob: 3 articles (08/2009 - 04/2003)
4.	Mills, Philippa B: 2 articles (10/2015 - 04/2005)
5.	Fargue, Sonia: 2 articles (10/2015 - 10/2013)
6.	Coburn, Stephen P: 2 articles (01/2015 - 01/2002)
7.	Wrenger, Carsten: 2 articles (01/2014 - 01/2009)
8.	Talwar, Dinesh: 2 articles (01/2012 - 07/2008)
9.	McMillan, Donald C: 2 articles (01/2012 - 07/2008)
10.	Gospe, Sidney M: 2 articles (01/2010 - 04/2006)

Related Diseases

1.	Seizures (Seizure) 03/01/2004 - "Treatment with high-dose pyridoxal phosphate eliminated his seizures." 06/01/2014 - "Median Pyridoxal-phosphate levels in patients with NS compared to patients with primary generalized seizures and community controls were not significantly different. " 03/01/2013 - "Seizures with decreased levels of pyridoxal phosphate in cerebrospinal fluid." 02/01/2002 - "Her seizures are perhaps not solely caused by pyridoxal phosphate deficiency. " 02/01/2002 - "The mechanism by which pyridoxal phosphate controls seizures in this patient is unknown. "
2.	Infantile Spasms (West Syndrome) 01/01/1987 - "Fifteen (12.7%) among 118 cases of the West syndrome were effectively treated by high-dose pyridoxal phosphate (PAL-P). " 12/01/1998 - "Eighteen children with West syndrome (5-11 months of age) were selected to receive an oral dose of pyridoxal phosphate, (20-50 mg/kg) for 14 d. " 01/01/1987 - "Treatment of the West syndrome with high-dose pyridoxal phosphate." 03/01/2004 - "A successful treatment with pyridoxal phosphate for West syndrome in hypophosphatasia." 01/01/1998 - "Combination therapy consisting of high-dose pyridoxal phosphate (40-50 mg/kg/day) and low-dose synthetic ACTH (0.01 mg/kg/day) was prescribed in 28 children with infantile spasms. "
3.	Schizophrenia (Dementia Praecox) 01/01/2015 - "Pyridoxal 5 phosphate may have some benefits in reducing the severity of tardive dyskinesia symptoms among individuals with schizophrenia. " 01/01/2015 - "Studies described as randomised controlled trials comparing the effectiveness pyridoxal 5 phosphate with placebo in the treatment of neuroleptic-induced tardive dyskinesia among patients with schizophrenia. " 01/01/1988 - "The effectiveness of combined phenazepam, lithium, haloperidol and metabolic drugs (alpha-tocopherol, pyridoxal phosphate, nicotinamide) treatment of patients with slow progredient schizophrenia is analyzed. " 01/01/2015 - "To determine the effectiveness of pyridoxal 5 phosphate (vitamin B6 or Pyridoxine or Pyridoxal phosphate) in the treatment of neuroleptic-induced tardive dyskinesia among people with schizophrenia and other related psychotic disorders. "
4.	Movement Disorders (Movement Disorder) 01/01/2015 - "Overall, pyridoxal 5 phosphate produced a significant improvement in tardive dyskinesia symptoms when compared with placebo, assessed by a change in Extrapyramidal Symptoms Rating Scale (ESRS) scores from baseline to the end of the first phase of the included studies (2 RCTs n = 65, RR 19.97, CI 2.87 to 139.19, low quality evidence). " 01/01/2015 - "While there are no known effective treatments for tardive dyskinesia to date, some reports suggest that pyridoxal 5 phosphate may be effective in reducing the severity of tardive dyskinesia symptoms. " 01/01/2015 - "However, the quality of evidence supporting the effectiveness of pyridoxal 5 phosphate in treating tardive dyskinesia is low, based on few studies, short follow-up periods, small sample sizes and inadequate adherence to standardised reporting guidelines for randomised controlled trials among the included studies." 01/01/2015 - "The endpoint tardive dyskinesia score (a measure of its severity) assessed with the ESRS, was significantly lower among participants on pyridoxal 5 phosphate compared to those on placebo (2 RCTs n = 60, MD -4.07, CI -6.36 to -1.79, low quality evidence).It was unclear whether pyridoxal 5 phosphate led to more side effects (n = 65, 2 RCTs, RR 3.97, CI 0.20 to 78.59, low quality evidence) or caused deterioration in tardive dyskinesia symptoms when compared to placebo (n = 65, 2 RCTs, RR 0.16, CI 0.01 to 3.14, low quality evidence). " 01/01/2015 - "Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia."
5.	Gyrate Atrophy 08/01/1981 - "Gyrate atrophy of the choroid and retina is caused by deficient activity of ornithine ketoacid aminotransferase, a pyridoxal phosphate dependent enzyme. " 07/01/1981 - "It is suggested that the in-vitro examination of the influence of pyridoxal phosphate on ornithine ketoacid transaminase activity in cultured fibroblasts may be useful in ascertaining the efficacy of vitamin B6 treatment in gyrate atrophy. "

Related Drugs and Biologics

1.	Valproic Acid (Valproate, Semisodium)
2.	Vitamin B 6
3.	Ornithine-Oxo-Acid Transaminase (Ornithine Aminotransferase)
4.	zonisamide (Zonegran)
5.	Pyridoxine (Pyridoxin)
6.	Pyridoxal
7.	Leucovorin (Folinic Acid)
8.	Threonine (L-Threonine)
9.	Branched-Chain Amino Acids
10.	Vitamins

Related Therapies and Procedures

1.	Stents
2.	Drug Therapy (Chemotherapy)
3.	Transplants (Transplant)
4.	Intraventricular Injections
5.	Renal Dialysis (Hemodialysis)